S&P 500   4,592.22 (+0.53%)
DOW   36,195.99 (+0.68%)
QQQ   389.47 (+0.16%)
AAPL   191.30 (+0.71%)
MSFT   372.83 (-1.60%)
META   323.74 (-1.04%)
GOOGL   131.66 (-0.66%)
AMZN   146.66 (+0.39%)
TSLA   238.73 (-0.56%)
NVDA   469.78 (+0.44%)
NIO   7.19 (-1.10%)
BABA   73.38 (-2.00%)
AMD   120.79 (-0.31%)
T   16.65 (+0.48%)
F   10.54 (+2.73%)
MU   75.76 (-0.47%)
CGC   0.59 (+5.96%)
GE   122.98 (+0.97%)
DIS   92.48 (-0.23%)
AMC   6.78 (+1.95%)
PFE   29.30 (-3.84%)
PYPL   59.18 (+2.73%)
XOM   104.14 (+1.36%)
S&P 500   4,592.22 (+0.53%)
DOW   36,195.99 (+0.68%)
QQQ   389.47 (+0.16%)
AAPL   191.30 (+0.71%)
MSFT   372.83 (-1.60%)
META   323.74 (-1.04%)
GOOGL   131.66 (-0.66%)
AMZN   146.66 (+0.39%)
TSLA   238.73 (-0.56%)
NVDA   469.78 (+0.44%)
NIO   7.19 (-1.10%)
BABA   73.38 (-2.00%)
AMD   120.79 (-0.31%)
T   16.65 (+0.48%)
F   10.54 (+2.73%)
MU   75.76 (-0.47%)
CGC   0.59 (+5.96%)
GE   122.98 (+0.97%)
DIS   92.48 (-0.23%)
AMC   6.78 (+1.95%)
PFE   29.30 (-3.84%)
PYPL   59.18 (+2.73%)
XOM   104.14 (+1.36%)
S&P 500   4,592.22 (+0.53%)
DOW   36,195.99 (+0.68%)
QQQ   389.47 (+0.16%)
AAPL   191.30 (+0.71%)
MSFT   372.83 (-1.60%)
META   323.74 (-1.04%)
GOOGL   131.66 (-0.66%)
AMZN   146.66 (+0.39%)
TSLA   238.73 (-0.56%)
NVDA   469.78 (+0.44%)
NIO   7.19 (-1.10%)
BABA   73.38 (-2.00%)
AMD   120.79 (-0.31%)
T   16.65 (+0.48%)
F   10.54 (+2.73%)
MU   75.76 (-0.47%)
CGC   0.59 (+5.96%)
GE   122.98 (+0.97%)
DIS   92.48 (-0.23%)
AMC   6.78 (+1.95%)
PFE   29.30 (-3.84%)
PYPL   59.18 (+2.73%)
XOM   104.14 (+1.36%)
S&P 500   4,592.22 (+0.53%)
DOW   36,195.99 (+0.68%)
QQQ   389.47 (+0.16%)
AAPL   191.30 (+0.71%)
MSFT   372.83 (-1.60%)
META   323.74 (-1.04%)
GOOGL   131.66 (-0.66%)
AMZN   146.66 (+0.39%)
TSLA   238.73 (-0.56%)
NVDA   469.78 (+0.44%)
NIO   7.19 (-1.10%)
BABA   73.38 (-2.00%)
AMD   120.79 (-0.31%)
T   16.65 (+0.48%)
F   10.54 (+2.73%)
MU   75.76 (-0.47%)
CGC   0.59 (+5.96%)
GE   122.98 (+0.97%)
DIS   92.48 (-0.23%)
AMC   6.78 (+1.95%)
PFE   29.30 (-3.84%)
PYPL   59.18 (+2.73%)
XOM   104.14 (+1.36%)

Akebia Therapeutics (AKBA) ESG Score & Sustainability Data

$1.08
+0.02 (+1.89%)
(As of 12:15 PM ET)
Compare
Today's Range
$1.02
▼
$1.09
50-Day Range
$0.80
▼
$1.18
52-Week Range
$0.28
▼
$1.84
Volume
508,709 shs
Average Volume
1.80 million shs
Market Capitalization
$203.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Key ESG Takeaways for Akebia Therapeutics

The key takeaways are AI-generated and highlight the main contributors behind the net impact scores of Akebia Therapeutics. The insights are based on millions of scientific articles, along with the company-specific product and service portfolio.
  • Akebia Therapeutics seems to create the most significant positive value in categories , , and . The largest positive contribution comes from its impact, which is driven by its Various other types of medication (V) and Clinical research services for physical health products.
  • Akebia Therapeutics uses resources or causes negative impacts mostly in categories , , and . The negative contribution in the impact category is driven by its Various other types of medication (V) and Clinical research services for physical health products.
  • To improve its net impact, a company can either grow its positive impacts, or reduce its negative impacts. For example, by doubling its Clinical research services for physical health business, Akebia Therapeutics would improve its net impact ratio by 7 percentage points.

AKBA Impact Ratio

Net impact ratio represents the net impact of a company. It is defined as the (positive impacts - negative impacts) / positive impacts. The maximum value for net impact ratio is 100%, representing a theoretical company with no negative impacts. The minimum value is -∞. Net scores depend on the value sets that determine the importance of different impact categories.
+55.6%
The default value set, where each category is given the same weight.

Value Sets Value sets can be used to assess how different stakeholder values or emphasis on certain values might affect the net impact ratio.

Millennials
Value set of millennials (b. 1980 - 1999), based on Upright's annual Impact at Work survey.
+59.0%
Most Wanted Workforce
Value set of the most wanted workforce, based on Upright's annual Impact at Work survey.
+44.3%
Society First
Value set that emphasizes society impacts over other impacts.
+3.4%
Knowledge First
Value set that emphasizes knowledge impacts over other impacts.
+73.4%
Health First
Value set that emphasizes health impacts over other impacts.
+76.6%

Akebia Therapeutics ESG Score + Net Impact Profile

ImpactNegativeScorePositive
+1.20
+1.20
+1.66
+1.66
+0.04
+0.04
-0.03
-0.03
+0.00
-0.56
-0.53
+0.03
0.00
+0.00
+1.26
+1.26
-0.00
+0.00
+0.00
-1.39
-1.39
-0.61
+3.63
+4.25
-0.03
+0.22
+0.25
+0.00
+0.00
-0.00
+0.03
+0.03
-0.01
+0.27
+0.28
-0.60
-0.58
+0.02
-0.36
-0.36
+0.01
-0.03
-0.03
+0.00
-0.10
-0.10
+0.00
-0.29
-0.29
+0.00

Upright Model Version 1.1.0
ESG Data Last Updated: June 14, 2023


About Upright's Net Impact Model

Upright Model

Upright's Net Impact Data quantifies the holistic value creation and impact of companies. It details both the negative and positive impacts a company has on the environment, health of people, society and knowledge, and forms a net sum of these costs and gains based on the economic costs of each impact category. The data is produced by Upright's Net Impact model, which is a mathematical model of the economy that produces continuously updated estimates of the net impact of companies by means of an information integration algorithm. The data is primarily sourced from the CORE open access database, which contains over 200 million scientific papers. Other sources of data include open databases published by the World Bank, IMF, WHO, OECD, IPCC, CDC and USDA.













Akebia Therapeutics ESG Score - Frequently Asked Questions

How is Akebia Therapeutics doing in terms of sustainability?

According to The Upright Project, which measures holistic value creation and impact of companies, Akebia Therapeutics has a net impact ratio of 55.6%, indicating an overall positive sustainability impact. Akebia Therapeutics seems to create the most significant positive value in the categories of Physical diseases, Taxes, and Creating knowledge. Akebia Therapeutics uses resources or causes negative impacts mostly in the categories of Scarce human capital, Physical diseases, and GHG emissions. Learn more on the sustainability of Akebia Therapeutics.


More ESG Stocks and Research Tools

Related Companies:
Stock Lists:
Sustainability Tools:
This page (NASDAQ:AKBA) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -